Агонисты гонадотропин-рилизинг-гормона и add-back-терапия

Закрыть метаданные

Рекомендуем статьи по данной теме:

Эндометриоз передней брюшной стенки и промежности после родоразрешения. Российский вестник акушера-гинеколога. 2022;(6):89-93

Современные подходы к медикаментозному лечению пациенток с сочетанными пролиферативными заболеваниями матки. Российский вестник акушера-гинеколога. 2022;(6):102-108

Влияние синдрома повышенной кишечной проницаемости на становление альтернативной формы гомеостаза перитонеальной жидкости за счет перестройки макрофагального звена при эндометриозе. Проблемы репродукции. 2022;(6):53-62

Вклад микробиоты эндометрия в развитие эндометриоза и аденомиоза у женщин репродуктивного возраста. Проблемы репродукции. 2022;(6):170-174

Особенности колоректальных резекций при глубоком инфильтративном эндометриозе. Хирургия. Журнал им. Н.И. Пирогова. 2022;(12):54-58

Деубиквитиназа и неконъюгированный убиквитин активируют воспаление микроокружения и боль в эутопическом и эктопическом эндометрии при эндометриозе. Проблемы репродукции. 2023;(1):9-18

Особенности взаимосвязи субпопуляционного состава и содержания цитокинов в периферической крови и перитонеальной жидкости женщин с эндометриозом. Проблемы репродукции. 2023;(1):19-32

Оценка эффективности диеногеста в терапии хронической тазовой боли у больных эндометриозом. Проблемы репродукции. 2023;(2):51-56

Эндометриоз-ассоциированный болевой синдром и спаечный процесс — новые аспекты патогенеза и возможности терапии. Проблемы репродукции. 2023;(2):93-100

Представлен анализ опубликованных работ по применению агонистов гонадотропин-рилизинг-гормона в гинекологической практике, показана их высокая эффективность при тяжелых формах заболеваний, рефрактерных к другим видам консервативной терапии. Проведен подробный анализ дополнительного назначения низких доз эстрогенов и/или прогестагенов, фитоэстрогенов, селективных модуляторов эстрогеновых рецепторов и селективных ингибиторов обратного захвата серотонина с целью купирования симптомов эстрогендефицита, в том числе потери минеральной плотности костной ткани, и представлены адаптированные схемы терапии для применения в клинической практике.

Ключевые слова:

агонисты гонадотропин-рилизинг-гормона

add-back-терапия

эндометриоз

бусерелин

эстрогендефицит

Авторы:

Пустотина О.А.

ЧОУ ДПО «Академия медицинского образования им. Ф.И. Иноземцева»

ORCID: 0000-0001-6117-7270

Дата поступления:

15.02.2023

Дата принятия в печать:

20.02.2023

Список литературы:

Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogues. N Engl J Med. 1991;324:2:93-103. https://doi.org/10.1056/NEJM199101103240205
Levine D, Kaufman L, Cuenca VG, Badawy SZ. Cell growth effects of leuprolide on cultured endometrioma cells. J Reprod Med. 2007;52:7:581-584.
Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, King K, Kvaskoff M, Nap A, Petersen K, Saridogan E, Tomassetti C, van Hanegem N, Vulliemoz N, Vermeulen N. ESHRE Endometriosis Guideline Group. ESHRE guideline: endometriosis. Hum Reprod Open. 2022;2022:2:hoac009. https://doi.org/10.1093/hropen/hoac009
Barra F, Grandi G, Tantari M, Scala C, Facchinetti F, Ferrero S. A comprehensive review of hormonal and biological therapies for endometriosis: latest developments. Expert Opin Biol Ther. 2019;19:4:343-360.
Prentice A, Deary AJ, Goldbeck-Wood S, Farquhar C, Smith SK. WITHDRAWN: Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2007;2:CD000346. https://doi.org/10.1002/14651858.CD000346.pub2
Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane database Syst Rev. 2010;8:2010:12:CD008475. https://doi.org/10.1002/14651858.CD008475.pub2
Surrey ES, Hornstein MD. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol. 2002;99:5 Pt 1:709-719. https://doi.org/10.1016/s0029-7844(02)01945-2
Georgiou EX, Melo P, Baker PE, Sallam HN, Arici A, Garcia-Velasco JA, Abou-Setta AM, Becker C, Granne IE. Long-term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with endometriosis. Cochrane Database of Systematic Reviews. 2019;Issue 11: Art. No.: CD013240. https://doi.org/10.1002/14651858.CD013240.pub2
Lethaby A, Puscasiu L, Vollenhoven B. Preoperative medical therapy before surgery for uterine fibroids. Cochrane Database Syst Rev. 2017;11:11:CD000547. https://doi.org/10.1002/14651858.CD000547.pub2
Osuga Y, Enya K, Kudou K, Hoshiai H. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women. Fertil Steril. 2019;112:5:922-929.e2. https://doi.org/10.1016/j.fertnstert.2019.07.013
Stratopoulou CA, Donnez J, Dolmans MM. Conservative management of uterine adenomyosis: medical vs. surgical approach. J Clin Med. 2021;10:21:4878. https://doi.org/10.3390/jcm10214878
Panay N, Fenton A. Severe PMS/PMDD — is it Time for a new approach? Climacteric. 2015;18:3:331-332.
Panay N. Treatment of premenstrual syndrome: a decision-making algorithm. Menopause Int. 2012;18:2:90-92.
Carr BR, Breslau NA, Givens C, Byrd W, Barnett-Hamm C, Marshburn PB. Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study. J Clin Endocrinol Metab. 1995;80:4:1169-1178. https://doi.org/10.1210/jcem.80.4.7714086
Chen J, Cao D, Yang J, Yu M, Zhou H, Cheng N, Wang J, Zhang Y, Peng P, Shen K. Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia International Journal of Gynecologic Cancer. 2022;32:12:1561-1567. https://doi.org/10.1136/ijgc-2022-003882
Hornstein MD, Surrey ES, Weisberg GW, Casino LA. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol. 1998;91:1:16-24. https://doi.org/10.1016/s0029-7844(97)00620-0
Orwoll ES, Yuzpe AA, Burry KA, Heinrichs L, Buttram VC Jr, Hornstein MD. Nafarelin therapy in endometriosis: longterm effects on bone mineral density. Am J Obstet Gynecol. 1994;171:1221.
Tahara M, Matsuoka T, Yokoi T, Tasaka K, Kurachi H, Murata Y. Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy («draw-back» therapy). Fertil Steril. 2000;73:4:799-804. https://doi.org/10.1016/s0015-0282(99)00636-6
Hull ME, Barbieri RL. Nafarelin in the treatment of endometriosis. Dose management. Gynecol Obstet Invest. 1994;37:4:263-264. https://doi.org/10.1159/000292574
Tse CY, Chow AM, Chan SC. Effects of an extended-interval dosing regimen of triptorelin depot on the hormonal profile of patients with endometriosis: prospective observational study. Hong Kong Med J. 2000;6:3:260-264.
Kang JL, Wang XX, Nie ML, Huang XH. Efficacy of gonadotropin-releasing hormone agonist and an extended-interval dosing regimen in the treatment of patients with adenomyosis and endometriosis. Gynecol Obstet Invest. 2010;69:2:73-77. https://doi.org/10.1159/00025868
American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. Management of symptomatic uterine leiomyomas: ACOG Practice Bulletin, Number 228. Obstet Gynecol. 2021;137:6:100-115. https://doi.org/10.1097/AOG.0000000000004401
Hornstein MD, Gibbons WE. Endometriosis: Long-term treatment with GRH agonists. UpToDate. 2022. https://sso.uptodate.com
Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol. 1992;166:2:740-745. https://doi.org/10.1016/0002-9378(92)91706-g
DiVasta AD, Feldman HA, Sadler Gallagher J, Stokes NA, Laufer MR, Hornstein MD, Gordon CM. Hormonal add-back therapy for females treated with gonadotropin-releasing hormone agonist for endometriosis: a randomized controlled trial. Obstet Gynecol. 2015;126:617-627.
Guzick DS, Huang LS, Broadman BA, Nealon M, Hornstein MD. Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. Fertil Steril. 2011;95:5:1568-1573. https://doi.org/10.1016/j.fertnstert.2011.01.027
Edmonds DK. Add-back therapy in the treatment of endometriosis: the European experience. Br J Obstet Gynaecol. 1996;103:14:10-13.
Zupi E, Marconi D, Sbracia M, Zullo F, De Vivo B, Exacustos C, Sorrenti G. Add-back therapy in the treatment of endometriosis-associated pain. Fertil Steril. 2004;82:5:1303-1308. https://doi.org/10.1016/j.fertnstert.2004.03.062
Stratopoulou CA, Donnez J, Dolmans MM. Conservative management of uterine adenomyosis: medical vs. surgical approach. J Clin Med. 2021;10:21:4878. https://doi.org/10.3390/jcm10214878
Cameron ST, Critchley HOD, Glasier AF, Williams AR, Baird DT. Continuous transdermal oestrogen and interrupted progestogen as a novel bleed-free regimen of hormone replacement therapy for postmenopausal women. Br J Obstet Gynaecol. 1997;104:1184-1190.
Mitwally MF, Gotlieb L, Casper RF. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. Menopause. 2002;9:4:236-241. https://doi.org/10.1097/00042192-200207000-00004
Sauerbrun-Cutler MT, Alvero R. Short- and long-term impact of gonadotropin-releasing hormone analogue treatment on bone loss and fracture. Fertil Steril. 2019;112:5:799-803. https://doi.org/10.1016/j.fertnstert.2019.09.037
Hurst BS, Gardner SC, Tucker KE, Awoniyi CA, Schlaff WD. Delayed oral estradiol combined with leuprolide increases endometriosis-related pain. JSLS. 2000;4:2:97-101.
Kim NY, Ryoo U, Lee DY, Kim MJ, Yoon BK, Choi D. The efficacy and tolerability of short-term low-dose estrogen-only add-back therapy during post-operative GnRH agonist treatment for endometriosis. Eur J Obstet Gynecol Reprod Biol. 2011;154:1:85-89. https://doi.org/10.1016/j.ejogrb.2010.08.008
Tanaka T. Effects of herbal medicines on menopausal symptoms induced by gonadotropin-releasing hormone agonist therapy. Clin Exp Obstet Gynecol. 2001;28:1:20-23.
Mortola JF. From GnRH to SSRIs and Beyond: Weighing the options for drug therapy in premenstrual syndrome. Medscape Womens Health. 1997;2:10:3.
Wu D, Hu M, Hong L, Hong S, Ding W, Min J, Fang G, Guo W. Clinical efficacy of add-back therapy in treatment of endometriosis: a meta-analysis. Arch Gynecol Obstet. 2014;290:3:513-523. https://doi.org/10.1007/s00404-014-3230-8
Fuldeore MJ, Marx SE, Chwalisz K, Smeeding JE, Brook RA. Add-back therapy use and its impact on LA persistence in patients with endometriosis. Curr Med Res Opin. 2010;26:3:729-736. https://doi.org/10.1185/03007990903582985
Al-Azemi M, Jones G, Sirkeci F, Walters S, Houdmont M, Ledger W. Immediate and delayed add-back hormonal replacement therapy during ultra long GnRH agonist treatment of chronic cyclical pelvic pain. BJOG. 2009;116:12:1646-1656. https://doi.org/10.1111/j.1471-0528.2009.02319.x
Kiesel L, Schweppe KW, Sillem M, Siebzehnrübl E. Should add-back therapy for endometriosis be deferred for optimal results? Br J Obstet Gynaecol. 1996;103:(suppl 14):15-17.
Morris EP, Rymer J, Robinson J, Fogelman I. Efficacy of tibolone as «add-back therapy» in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids. Fertil Steril. 2008;89:2:421-428.
Al-Hendy A, Lukes AS, Poindexter AN, Venturella R, Villarroel C, Critchley HOD, Li Y, McKain L, Arjona Ferreira JC, Langenberg AGM, Wagman RB, Stewart EA. Treatment of uterine fibroid symptoms with relugolix combination therapy. N Engl J Med. 2021;384:7:630-642.
Fuldeore MJ, Marx SE, Chwalisz K Smeeding JE, Brook RA. Add-back therapy use and its impact on LA persistence in patients with endometriosis. Curr Med Res Opin. 2010;26:3:729-736.
Клинические рекомендации РОАГ, МЗ РФ. Эндометриоз. 2020.
Клинические рекомендации РОАГ, МЗ РФ. Миома матки. 2020.
Zheng Q, Mao H, Xu Y, Zhao J, Wei X, Liu P. Can postoperative GnRH agonist treatment prevent endometriosis recurrence? A meta-analysis. Arch Gynecol Obstet. 2016;294:1:201-207.
Evers JL. The second-look laparoscopy for evaluation of the result of medical treatment of endometriosis should not be performed during ovarian suppression. Fertil Steril. 1987;47:3:502-504. https://doi.org/10.1016/s0015-0282(16)59062-1
Bedaiwy MA, Casper RF. Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain. Fertil Steril. 2006;86:1:220-222. https://doi.org/10.1016/j.fertnstert.2005.12.030
Szendei G, Hernádi Z, Dévényi N, Csapó Z. Is there any correlation between stages of endometriosis and severity of chronic pelvic pain? Possibilities of treatment. Gynecol Endocrinol. 2005;21:2:93-100. https://doi.org/10.1080/09513590500107660
Lee DY, Bae DS, Yoon BK, Choi D. Post-operative cyclic oral contraceptive use after gonadotrophin-releasing hormone agonist treatment effectively prevents endometrioma recurrence. Hum Reprod. 2010;25:12:3050-3054.
Choi SH, Kim SE, Lim HH, Lee DY, Choi D. Efficacy of post-operative medication to prevent recurrence of endometrioma: cyclic oral contraceptive (OC) after gonadotropin-releasing hormone (GnRH) agonist versus dienogest. J Korean Med Sci. 2022;37:26:e207. https://doi.org/10.3346/jkms.2022.37.e207

Закрыть метаданные